Thivolet J, Nicolas J F, Kanitakis J, Lyonnet S, Chouvet B
Clinique Dermatologique, Hôpital E. Herriot, Lyon, France.
Br J Dermatol. 1990 Mar;122(3):405-9. doi: 10.1111/j.1365-2133.1990.tb08290.x.
Ten patients suffering from either discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) were treated with interferon alpha 2a. Eight received low or intermediate doses (18-45 x 10(6) U/week) for a short period of time (4-8 weeks), with marked improvement of skin lesions in six, an exacerbation in one patient and no change in the other. Two patients with SCLE received high doses (100-120 x 10(6) U/week) over 12 weeks, with complete clearing of the lesions in one and a marked improvement in the other. The responses were of short duration and within a few weeks of stopping treatment all who had improved or cleared relapsed. The side-effects in all the patients were fever and a flu-like syndrome which necessitated a reduction of the dose in one case. In two patients there were increases in the liver enzyme levels, but no haematological toxicity was noted.
10名患有盘状红斑狼疮（DLE）或亚急性皮肤型红斑狼疮（SCLE）的患者接受了α-2a干扰素治疗。8名患者接受了低剂量或中等剂量（18 - 45×10⁶单位/周）的短期治疗（4 - 8周），其中6名患者的皮肤病变明显改善，1名患者病情加重，另1名患者无变化。2名SCLE患者接受了高剂量（100 - 120×10⁶单位/周）的12周治疗，其中1名患者的病变完全消退，另1名患者有明显改善。这些反应持续时间较短，在停止治疗后的几周内，所有病情改善或消退的患者均复发。所有患者的副作用为发热和类似流感的综合征，其中1例患者因此需要减少剂量。2名患者的肝酶水平升高，但未观察到血液学毒性。
